Literature DB >> 33430887

Pancreatic ductal adenocarcinoma and distal cholangiocarcinoma: a proposal of preoperative diagnostic score for differential diagnosis.

Edoardo Maria Muttillo1, Antonio Ciardi2, Raffaele Troiano1, Paolina Saullo1, Gabriele Masselli2, Marianna Guida2, Alessandra Tortora2, Isabella Sperduti3, Giulio Marinello1, Piero Chirletti1, Roberto Caronna4.   

Abstract

PURPOSE: The differential diagnosis between primary adenocarcinoma of the pancreas head and distal cholangiocarcinoma remains a clinical challenge. Recent studies have shown important differences in terms of survival between these tumors. Therefore, different treatments should be considered, but the preoperative histological diagnosis is still difficult. Aim of this study is to create a preoperative diagnostic score for differential diagnosis between primary pancreatic adenocarcinoma and primary distal cholangiocarcinoma.
METHODS: One hundred eighty consecutive patients who underwent pancreaticoduodenectomy at Sapienza University of Rome from January 2010 to December 2019 were retrospectively analyzed. Inclusion criteria were pancreatic or biliary histologic origin obtained by definitive postoperative histological examination. Exclusion criteria were diagnosis of ampullary carcinoma, non-ampullary duodenal adenocarcinoma, pancreatic metastasis, and benign disease. One hundred one patients were considered eligible for the retrospective study. Preoperative biological, clinical, and radiological parameters were considered.
RESULTS: CRP > 10 mg/dL (p = 0.001), modified Glasgow Prognostic Score 2 (p = 0.002), albumin < 35 g/L (p = 0.05), CA 19-9 > 230 U/mL (p = 0.001), and Wirsung diameter > 3 mm (p < 0.001) were significant at univariate logistic analysis. Multivariate logistic analysis has shown that parameters independently associated with primary pancreatic adenocarcinoma were CRP > 10 mg/dL (p = 0.012), CA 19-9 > 230 U/mL (p = 0.043), and diameter of the Wirsung > 3 mm (p = 0.005). Through these parameters, a diagnostic score has been developed to predict a primary pancreatic adenocarcinoma when > 1 and a primary distal cholangiocarcinoma when < 1.
CONCLUSION: This feasible and low-cost diagnostic score could have a potential impact to differentiate pancreatic cancer histologic origin and to improve target therapeutic strategy.

Entities:  

Keywords:  Differential diagnosis; Pancreatic head carcinoma; Pancreaticoduodenectomy; Preoperative diagnosis; Primary distal cholangiocarcinoma; Primary pancreatic adenocarcinoma

Mesh:

Year:  2021        PMID: 33430887      PMCID: PMC7802249          DOI: 10.1186/s12957-021-02120-w

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  32 in total

Review 1.  Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.

Authors:  Ulla Klaiber; Carl-Stephan Leonhardt; Oliver Strobel; Christine Tjaden; Thilo Hackert; John P Neoptolemos
Journal:  Langenbecks Arch Surg       Date:  2018-11-05       Impact factor: 3.445

2.  Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline.

Authors:  J-M Dumonceau; M Polkowski; A Larghi; P Vilmann; M Giovannini; J-L Frossard; D Heresbach; B Pujol; G Fernández-Esparrach; E Vazquez-Sequeiros; A Ginès
Journal:  Endoscopy       Date:  2011-08-12       Impact factor: 10.093

3.  Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer.

Authors:  Ryoichi Miyamoto; Tatsuya Oda; Shinji Hashimoto; Tomohiro Kurokawa; Keisuke Kohno; Yoshimasa Akashi; Yusuke Ohara; Keiichi Yamada; Tsuyoshi Enomoto; Nobuhiro Ohkohchi
Journal:  Pancreas       Date:  2017-01       Impact factor: 3.327

4.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

5.  Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.

Authors:  Teiichi Sugiura; Katsuhiko Uesaka; Hideyuki Kanemoto; Takashi Mizuno; Keiko Sasaki; Hiroyoshi Furukawa; Kazuya Matsunaga; Atsuyuki Maeda
Journal:  J Gastrointest Surg       Date:  2012-03-13       Impact factor: 3.452

6.  Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer.

Authors:  Zuqiang Liu; Kaizhou Jin; Meng Guo; Jiang Long; Liang Liu; Chen Liu; Jin Xu; Quanxing Ni; Guopei Luo; Xianjun Yu
Journal:  Ann Surg Oncol       Date:  2016-09-20       Impact factor: 5.344

Review 7.  Preoperative tissue diagnosis for tumours of the pancreas.

Authors:  W Hartwig; L Schneider; M K Diener; F Bergmann; M W Büchler; J Werner
Journal:  Br J Surg       Date:  2009-01       Impact factor: 6.939

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.

Authors:  Eva Versteijne; Casper H J van Eijck; Cornelis J A Punt; Mustafa Suker; Aeilko H Zwinderman; Miriam A C Dohmen; Karin B C Groothuis; Oliver R C Busch; Marc G H Besselink; Ignace H J T de Hingh; Albert J Ten Tije; Gijs A Patijn; Bert A Bonsing; Judith de Vos-Geelen; Joost M Klaase; Sebastiaan Festen; Djamila Boerma; Joris I Erdmann; I Quintus Molenaar; Erwin van der Harst; Marion B van der Kolk; Coen R N Rasch; Geertjan van Tienhoven
Journal:  Trials       Date:  2016-03-09       Impact factor: 2.279

10.  Association Between the Incidence of Pancreatic Fistula After Pancreaticoduodenectomy and the Degree of Pancreatic Fibrosis.

Authors:  Yong Deng; Baixiong Zhao; Meiwen Yang; Chuanhong Li; Leida Zhang
Journal:  J Gastrointest Surg       Date:  2018-01-12       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.